# Title: The gut microbiome associated with LGI1- and CASPR2-antibody encephalitis.

4 Main Manuscript

Authors: Edmund Gilbert<sup>1,2</sup>, Sophie Binks<sup>3,4</sup>, Valentina Damato<sup>5</sup>, Christopher Uy<sup>6</sup>, Paula Colmenero<sup>6</sup>,
 Mohamed Ibrahim Khalil<sup>1,2</sup>, Marcus O'Brien<sup>7</sup>, Marcus Claesson<sup>7,8,9</sup>, John F Cryan<sup>7,9</sup>, Norman

7 Delanty<sup>1,2</sup>, Sarosh R Irani<sup>3,10</sup>\*, Gianpiero L Cavalleri<sup>1,2</sup>\*

8 9

\* Authors contributed equally.

10

11 Affiliations:

12 1. School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, 13 Ireland. 2. FutureNeuro SFI Research Centre, Royal College of Surgeons in Ireland, Dublin, Ireland. 14 3. Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, 15 16 University of Oxford, Level 3, West Wing, John Radcliffe Hospital, Oxford, OX3 9DS, UK. 4. Dept of Neurology, John Radcliffe Hospital, Oxford, OX3 9DU. 17 5. Department of Neurosciences Drugs and Child Health, University of Florence, Florence, Italy. 18 6. Oxford Centre for Microbiome Studies, Kennedy Institute, University of Oxford, Oxford, OX3 19 20 7DQ, UK.SeqBiome Ltd., Moorepark Food Research Centre, Teagasc, Fermoy, P61 C996 Cork, Ireland 21 7. APC Microbiome Ireland, University College Cork, T12 YT20 Cork, Ireland. 22 23 8. School of Microbiology, University College Cork, T12 YT20 Cork, Ireland. 24 9. Department of Anatomy and Neuroscience, University College Cork, T12 YT20 Cork, Ireland. 25 10. Departments of Neurology and Neurosciences, Mayo Clinic, Jacksonville, Florida, USA.

#### 27 Abstract

28 Autoimmune encephalitis is a cause of brain inflammation characterised by auto-antibodies which 29 target cell surface neuronal proteins, and lead to neuronal dysfunction. In older people, common 30 forms are encephalitis with autoantibodies to leucine-rich glioma inactivated protein 1 (LGI1) and 31 contactin associated protein like 2 (CASPR2), whose presentation includes frequent focal seizures. 32 The exact cause of these autoantibodies remain unknown, but established predispositions include 33 overrepresented human leukocyte antigen (HLA) alleles. Yet, these alleles are themselves common in 34 the healthy ancestry-matched population. One potential aetiological hypothesis is that an 35 environmental trigger, such as the gut microbiome, interacts with a genetically predisposed 36 individual. To investigate this, we studied 47 patients with leucine-rich glioma-inactivated 1 (LGI1)- or 37 contactin-associated protein 2 (CAPSR2)-antibody encephalitis (LGI1/CASPR2-Ab-E) and 37 38 familial/environmentally matched controls, and performed metagenomic shotgun sequencing, to 39 describe compositional and functional differences in the gut microbiome. We observed that 40 LGI1/CASPR2-Ab-E gut microbiomes exhibited a significant reduction in the ratio of Firmicutes and 41 Bacteroidetes phyla, which associated with dosage of HLA susceptibility alleles in LGI1-Ab-E patients. 42 Furthermore, we identified differences in functional gene profiles in the gut microbiome that led to a 43 reduction of neuroinflammatory protective short-chain-fatty-acids (SCFA) in LGI1-Ab-E patients. 44 Taken together, our results suggest that a compositional shift in the gut microbiome of LGI1/CASPR2-45 Ab-E associates with a neuroinflammatory state, possibly through the reduction of SCFA production. 46 Our study highlights the potential of the gut microbiome to explain some of the complex condition 47 and unravel aetiological questions. Validation studies with greater sample sizes are recommended.

# 49 Introduction

Autoimmune encephalitis (AE) is characterised by the presence of autoantibodies with pathogenic 50 potential which target cell surface neuronal proteins<sup>1-3</sup>. Among the most common autoantibodies 51 detected in AE are those which bind leucine-rich glioma inactivated protein 1 (LGI1) and contactin 52 53 associated protein like 2 (CASPR2). Many of these patients typically have very frequent, focal seizures 54 in addition to altered mood, personality change, and cognitive impairment<sup>4</sup>. This semiology of these seizures can be pathognomonic, as is well-established for patients with faciobrachial dystonic 55 seizures in association with LGI1-antibodies<sup>5-7</sup>. In addition, other unusual semiologies in LGI1-56 antibody encephalitis (LGI1-Ab-E) include thermal, piloerection, autonomi and emotional events<sup>8,9</sup>. 57 Patients with CASPR2-antibodies also have very frequent focal seizures <sup>10-12</sup>. These clinical 58 observations imply that autoantibodies mediate forms of seizures which are likely to have 59 60 characteristic, and sometimes novel, underlying molecular mechanisms.

61 In addition to distinctive clinical features, these AE patients are often anti-seizure medication (ASM) 62 resistant, but show beneficial responses to immunotherapies, including corticosteroids, plasma 63 exchange, and intravenous immunoglobulins<sup>5,6,13,14</sup>. Yet, despite immunotherapies and ASMs, more 64 than 70% of patients are left with long term deficits, which impair quality of life<sup>5,15,16</sup>. In addition, 65 around 40% of people treated with immunotherapies experience adverse drug effects<sup>5,6</sup>, and in the 66 case of LGI1-Ab-E up to 20% develop chronic epilepsy<sup>17</sup>. Hence there is an unmet need for 67 personalised immunotherapies that could be safe and effective in the long term.

68 Despite its potential to explain causation and address therapeutic needs, the aetiology of these 69 diseases is poorly understood. Recent works have demonstrated that more than 90% of patients with LGI1-antibodies carry specific class-II HLA alleles, namely HLA-DRB1\*07:01 (OR: 26.4 [CI=8.5-81.5]<sup>18</sup>, 70 OR: 85.5 [CI=10.4-699.6]<sup>19</sup>). Whereas CAPSR2-antibody AE show a strong but distinct HLA profile with 71 an over-representation of HLA-DRB1\*11:01<sup>20</sup> (OR: 9.4 [CI=4.6-19.3]<sup>21</sup>). A striking feature of these 72 genetic findings is the relatively common underlying population frequencies of the HLA risk alleles. 73 74 The HLA-DRB1\*07:01 allele, for example, is also carried by 27% of healthy European-ancestry 75 populations<sup>18,21</sup> (~12% globally<sup>22</sup>) and HLA-DRB1\*11:01 is present in 9% of the general Europeanancestry population<sup>21</sup> (~5% globally, maximal in Europe<sup>22</sup>). Whilst these strong HLA Class II 76 associations clearly implicate T cells in disease pathogenesis, their high general population 77 frequencies only partially explain disease causation. Hence, we examined potential contributory 78 79 environmental triggers.

The gut microbiome elegantly provides an interface to explain such an environmental trigger. Indeed, in a variety of autoimmune central nervous system diseases, there is growing evidence for an aetiological link between the gut microbiome and the brain, principally via innate immunity and Tcells<sup>23-25</sup>. In several autoimmune diseases, skews in gut microbial populations have been discovered which may predispose to the illness<sup>23, 26-28</sup>. Further, in autoantigen-specific illnesses, a distinctive microbial signature may provide a similarly elegant link to the LGI1 and CASPR2 autoantigens through molecular mimicry.

Here, we investigated the gut microbiome in patients with LGI1- and CASPR2-Ab-E. We also collected stool and salivary DNA from matched but unaffected relatives, close family members, or friends. We sought to; 1) determine if species abundance or diversity in the gut microbiome was significantly different between healthy and affected family members, 2) characterise potential functional differences in these microbiotas, and finally 3) investigate the evidence of LGI1 sequence homologues within the gut microbiota of LGI1-Ab-E patients.

# 93 **Results**

#### 94 Recruitment and Cohort

We recruited 47 patients with LGI1- (n=43), CASPR2-antibody (n=3), or double positive LGI1/CASPR2-95 96 antibody (n=1) encephalitis, henceforth collectively referred to as LGI1/-CASPR2-Ab-E. In parallel, we 97 recruited matched healthy controls (HC, n=37) through close family members who were typically a 98 domestic partner (see Table 1). We isolated both genomic DNA from blood and gut microbiome DNA 99 from stool (see Methods). All cases and HC were consistent with British- or Irish-like ancestry in 100 comparison to ancestry controls (Supp Figure 1). Tissue typing confirmed an enrichment of the HLA 101 DRB\*07:01 allelotype in LGI1 patients (Table 1) compared to SNP genotype imputation of HLA alleles 102 in HC.

## 103 Gut Microbiome Composition

We first compared the composition of the gut microbiome in cases versus controls. We generated gut microbiome genomic profiles from paired-end metagenomic shotgun sequencing (see Methods and Supp Figure 2-3) and investigated composition changes with differential abundance and alpha and beta diversity analysis. The shotgun sequencing generated an average of 8.7 million paired end reads per sample where 84% of these reads passed the adapter trimming and quality filtering stage. An average of 91% of reads passed quality control and were classified using DNA species abundance estimators, *Kraken2* and *Bracken*.

111 The general compositional profile of cases and HC were consistent with the expected common human gut microbiome species such as *Bacteroides* or *Faecalibacterium*<sup>29</sup> (Figure 1A). We tested for 112 differences in abundance of individual species and identified no statistically significant differences 113 114 that survived correction for multiple testing (Table 2). Given the rarity of this disease and the fine-115 grained nature of individual species composition, the 16 most differentially abundant species are 116 reported with uncorrected p-values of < 0.05 (Table 2, Supp Data 2). Several of the species nominally 117 enriched in LGI1-CASPR2-Ab-E cases are also associated with the human oral and small intestinal 118 microbiome (e.g., Streptococcus parasanguinis, Streptococcus salivarius, Bifidobacterium dentium, 119 and various Veillonella).

120 To complement and extend this fine-grained species analysis, we simultaneously investigated phyla-, 121 genera-, and species-level enrichment between cases and controls using linear discriminant analysis 122 (LDA) (Figure 2, Supp Data 3). Supportive of previous species-level analysis, our LDA results also 123 provide evidence of human oral and small intestinal species of the Veillonella and Streptococcus 124 genera enriched in cases. In addition, our cases were enriched for the Enterococcus and Haemophilus D genera, with depletion of the Dorea and Coprococcus genera, and the Firmicutes phylum (recently 125 renamed Bacillota<sup>30,31</sup>). Beyond these depletions in HCs, we also observe a depletion specifically of 126 127 Bifidobacterium longum in cases (Figure 2).

From the LDA, the differential balance of the *Firmicutes* and *Bacteroidetes* phyla in cases and controls was of interest. Whilst changes in the *Firmicutes/Bacteroidetes* (F/B) ratio has been implicated in some human health-related traits<sup>32-34</sup>, this remains debatable<sup>32</sup>. We investigated such large-scale changes in the context of our modest sample size. As expected<sup>33</sup> these two Phyla account for the majority of phyla represented in the analysis - 52% + 39.8% (91.2% - Cases) and 30.4% + 61.7% (92.1% - HC). Although the F/B ratio was higher in controls (2.35) than cases (1.21), but this was not statistically significant (Wilcoxon Rank Sum p-value = 0.060) (**Supp Figure 4**).

Considering this F/B ratio difference between cases and controls we explored whether the dosage of
 HLA-DRB1\*07:01 impacts this F/B composition. Analysing the F/B ratio in HC and the LGI1-Ab-E cases

137 (as these were the largest case subtype) (Supp Figure 4), we found the F/B ratio to be significantly 138 lower in LGI1 positive cases relative to HCs (cases: 1.21, HCs: 2.35, Wilcox two-sided p-value: 0.032). 139 As expected, we found an enrichment of HLA-DRB1\*07:01 heterozygotes in LG/1-Ab-E cases versus controls (HWE exact p-value: 3 x 10<sup>-5</sup>) but not in controls (exact p-value: 0.16) (Supp Figure 5). We 140 141 observed the F/B ratio to decrease as a measure of HLA-DRB1\*07:01 dosage (Pearson's product-142 moment correlation = -0.31 (95% confidence intervals -0.56 to -0.006), p-value = 0.046). The same 143 pattern was no observed in the HCs (p-value = 0.95) (Supp Figure 5). Overall, this is the first hint of 144 gut composition differences between LGI1-Ab-E cases and controls associated with HLA-DRB1\*07:01 145 genotype.

146 We next investigated within-gut and between-gut diversity. Testing within-gut with Chao1, Simpson, 147 and Shannon alpha diversity measures we found evidence of subtle differences between case and HC 148 status – consistent with the observations from differential species analysis and LDA. We observed 149 Simpson alpha diversity to be significantly enriched in HC compared to cases (p-value = 0.0313), but 150 not Shannon (Shannon p-value = 0.1112) (Figure 1B, Supp Figure 6). Investigating between-gut 151 diversity we performed principal component analysis (PCA) of Aitchison distances of this abundance 152 data. We observed a borderline difference between cases and HC along principal component 2 (p-153 value = 0.083) (Figure 1C, Supp Figure 7). We also observe significant differences between dietary 154 variables and these principal components (Supp Data 4), though the uneven sampling size or 155 extremes in scale (such as vitamin most B12 consumption is "infrequent" or "daily") leads us to 156 caution against these dietary-based observations.

#### 157 Functional Characteristics

We next sought to extend the suggestive findings of differences in case-control gut microbiome 158 profiles, characterising function through KEGG modules and pathways<sup>35</sup> using HUMAnN3<sup>36</sup> (see 159 Methods). We tested both high-level KEGG modules and lower-level pathways for differential 160 abundance using Aldex2<sup>37</sup>, using an uncorrected p-value of 0.05 similar to our differential species 161 analysis (Table 3, Supp Data 5-6). We observed three KEGG modules to be significantly different in 162 163 cases and controls, all enriched in HC. These three modules are particularly interesting in the context of epilepsy. Microbial coenzyme A (CoA) is a key source of short chain fatty acids (SCFA) in the gut<sup>28</sup>, 164 where SCFAs are protective for neuroinflammation and seizure<sup>38</sup> and epilepsy in general<sup>39</sup>. Ornithine 165 acts as a precursor to CoA in its acetyl-CoA form<sup>40</sup> and histidine acts as a precursor to ornithine<sup>41</sup>. Of 166 the KEGG pathways all but pentose and glucuronate interconversions (KEGG pathway map00040) 167 168 were also enriched in HCs. In PCA of these KEGG pathway differences, we observe significant 169 clustering of cases versus HC on principal component three (Supp Figure 8) (p-value = 0.044) -170 though this significant clustering was not found in PCA of KEGG module differences (Supp Figure 9).

171 Finally, we tested the evidence that the gut microbiome of LGI1-Ab-E patients contains potential 172 bacterial homologues of the human LGI1, searching the RefSeq database for LGI1 homologues with 173 blastp (see Methods for quality cutoffs). We identified 13 organisms to contain such homologues 174 (Supp Data 7), however the majority potential homologues are annotated as "leucine-rich" or 175 "hypothetical", and nearly all organisms in which these homologues are observed are typically found 176 in marine environments. Mapping these potential homologues to the metagenomic data of our LGI1-177 Ab-E cases, we do not observe any hits and no evidence of their presence in the gut microbiome of 178 LGI1-Ab-E cases.

# 179 Discussion

180 This metagenomic analysis of the gut microbiome in 47 patients with LG11/-CASPR2-Ab-E, matched 181 with 27 HC with paired genomic data suggests a potential compositional bias in the gut microbiome 182 of AE. Together our results suggest subtle taxa compositional changes in cases with these differences 183 associated with HLA-DRB1\*07:01 dosage. Further this compositional change was associated with 184 depletion of KEGG modules linked to SCFA generation in cases.

185

We primarily observed that the general gut microbiome of individuals with LG11/-CASPR2-Ab-E appeared largely consistent with a normal microbiome composition with high abundance of common microbiome species<sup>29</sup>. We therefore infer that LG11-CASPR2-Ab-E is not characterised by a large difference in microbiome composition driven by specific species. The most positive signal of differing microbiome composition between cases and controls is the enrichment of *Bifidobacterium Longum* in HC. Interestingly, this species has been observed to exert beneficial health effects, on the human gut<sup>42</sup>, inflammation<sup>27</sup>, and potentially reducing cytotoxic effects of certain ASMs<sup>43</sup>.

193

194 Instead, linear discriminant analysis highlights several taxa potentially enriched in either our cases or 195 controls, with some of these taxa previously associated with traits relevant to LGI1-CASPR2-Ab-E. 196 Several genera enriched in our cases have been associated with neurological conditions and allows 197 us to place our results into the context of the interplay of the microbiome and neuroinflammation 198 and epilepsy. Streptococcus, our strongest signal, has been found to be associated with focal epilepsy 199 in children<sup>44</sup> where in a small sample (n=10) the authors posit a neuroinflammatory model. Indeed, a mouse model of intestinal inflammation increases convulsant activity and ASM resistance<sup>45</sup>. In 200 addition to Streptococcus, the taxa Enterococcus<sup>46</sup> and Roseburia<sup>47</sup> have been found to be associated 201 202 with intractable childhood or drug-resistant epilepsy (respectively), and Roseburia in another study of LGI1-Ab-E<sup>48</sup>. The genera Coprococcus and Dorea are both enriched in our HC. These have been 203 associated with drug-resistant epilepsy<sup>47</sup>, but Coprococcus is also noted for its anti-inflammatory 204 205 associations<sup>33</sup> and is depleted in our cases. Our results would support larger, multi-centre studies of 206 the role of the gut microbiome in epilepsy healthcare, from ASM use to disease aetiology and 207 longitudinally from onset to chronic as has been achieved in the cases reported here.

208

209 In addition to subtle genera or species differences, our primary observation is the reduction of F/B 210 ratio in LGI1-Ab-E cases compared to HC. This reduction in the F/B ratio appears to be associated with HLA DRB\*07:01 allele dosage. The frequency of HLA DRB\*07:01 in our cases (91% carriers) 211 matches that observed in cohorts of similar ancestry<sup>19,21</sup>, and our AE cases were primarily LGI1 212 positive (n=43/47) – in keeping with literature<sup>10</sup>. To our knowledge this is the first observation linking 213 gut microbiome compositional changes to the major LGI1-Ab-E genetic risk locus. Encouragingly a 214 215 reduction of the F/B ratio and taxa diversity has been associated in another gut microbiome study of 216 LGI1-Ab-E in a cohort of 15 patients of Han Chinese ancestry compared to 25 matched controls using 217 16S rRNA sequencing<sup>48</sup>. Although the Chinese investigation did not consider HLA genotypes, together 218 our studies show evidence that a subtle shift in taxa composition measured by the F/B ratio is 219 associated with LGI1-Ab-E and is consistent with an inflammatory disease model<sup>48</sup>. That said, for 220 obesity, one of the first traits where the F/B ratio was suggested as a biomarker, results are frequently discrepent<sup>32</sup> and that phyla encompass a wide variety of taxa with differing functional 221 attributes<sup>26</sup>. Wider and further studies are warranted in neuroinflammatory and epilepsy traits, to 222 223 investigate the veracity of our observation. These F/B ratio findings appear to be complemented by 224 our functional characteristics results. We find KEGG modules that are nominally depleted in cases, and these modules are associated with CoA synthesis, itself leading to the synthesis of SCFA, which 225 are believed to have an anti-neuroinflammatory effect<sup>39,48</sup>. Taken together with the enrichment of 226 227 species such as Bifidobacterium Longum in HC, our results suggest a model whereby compositional 228 changes in the gut microbiome are associated with functional shifts linked to a loss of 229 neuroprotective SCFA in a context of a specific HLA class II genotype.

#### 230

231 In addition to these observed compositional and functional changes, we found in LGI1/-CASPR2-Ab-E 232 cases there is an enrichment of species that are normally associated with the oral or small intestinal microbiomes. It has been observed that corticosteroids impact saliva quality<sup>49</sup> in a way that could 233 result in accelerated movement of matter though the digestive system, leading to abundance of oral 234 or small intestinal communities. Corticosteroids are a commonly prescribed treatment in of AE<sup>5,6</sup> as 235 236 early immune therapy and a majority of our patients have been exposed to this treatment (Table 1) -237 therefore it is a possibility that this observation is driven by treatment and not underlying aetiology. 238 In a linear discriminant analysis comparing cases that have a history of steroid treatment versus case 239 with no history, and versus HCs, we find evidence that this signal is driven by steroid use history 240 (Supp Figure 10). Furthermore, there is previous evidence ASMs may also impact the gut microbiota<sup>43</sup> as does the anti-epileptic ketogenic diet<sup>50,51</sup>. In the latter case, none of the LGI1-241 CASPR2-Ab-E patients included in this study were or had been on a ketogenic diet. 242

243

244 The primary limitation of this study was cohort size. LGI1-CASPR2-Ab-E is a rare disease which can 245 impact cognitive function, and despite recruitment across the UK and Ireland, only 47 cases were 246 available for analysis. Further, we have studied chronic cases, which may have a different 247 composition to the microbiome of cases with an acute onset. We expect that the sample size 248 constraint impacted our ability to detect more subtle differences between LGI1-CASPR2-Ab-E cases 249 and controls, and limits the statistical power of sub-group analysis. Combining with other AE cohorts 250 of a similar dietary and pharmacological background may provide novel insights, though future care 251 will need to be taken in harmonising gut microbiome sequence generation methods to ensure inter-252 study comparisons are possible. Compositional changes in the microbiome have been associated with ageing<sup>52</sup>, and we lacked information on the ages of most of our HC. However, we expect our 253 cases and controls to be largely aged-matched (and background matched) as our HC are 254 255 predominantly spousal or sibling in relationship.

256

257 To conclude, our work suggests that LGI1-CASPR2-Ab-E is associated with specific compositional 258 changes in the gut microbiome, shifting the balance between the predominant taxa Firmicutes and 259 Bacteroidetes in favour of Bacteroidetes. This ratio change is associated with the significant HLA risk 260 allelotype DRB\*07:01 in cases only and matches previous studies of LGI1-Ab-E cases. This profile is 261 also associated with a shift in functional microbial activity linked to reduced SCFA levels. Given our 262 low sample size, reflective of this rare condition and its effect on statistical power, the exact effect 263 the microbiome plays in disease pathogenesis and/or progression remains unclear. However, our 264 results show a role in a subtle compositional and functional change that is consistent with a 265 neuroinflammatory model and case-specific effect in the HLA DRB\*07:01 allelotype. Further work 266 with expanded sample sets and coordinated sequencing protocols appears to be the next step in 267 elucidating the potential trigger for this rare and refractory epilepsy.

# 268 Methods

#### 269 Ethics Approval

This study was approved by ethics committees at the Royal College of Surgeons in Ireland (under protocol REC1631), and Oxford University (under protocol number 16/YH/0013). Ethics for this study was approved in the UK by Yorkshire & The Humber - Leeds East Research Ethics Committee (16/YH/0013). All patients gave written informed consent.

#### 274 Recruitment

275 Eligible patients were aged >18 with a diagnosis of autoimmune encephalitis/epilepsy and a positive 276 test for LGI1 and/or CASPR2 antibodies in serum and/or CSF. HCs were spouses, relatives or friends 277 attending clinic or subsequently recruited from the community, preferentially recruiting genetic 278 relatives, or co-habiting relatives. All participants gave informed consent or assent was given by next 279 of kin. Saliva and stool samples were gathered in the home environment and posted via secure 280 biokit. Stool was collected using a Omnigene Gut stool collection kit (DNA Genotek, OM-200). Saliva 281 was collected using Isohelix GeneFix saliva collection kits (Isohelix, GFX-02). Samples were posted to 282 the lab using an overnight tracked-return service and stored at -80°C on arrival. At the time of 283 sampling study participants also completed a questionnaire covering toileting routine, bowel habits, 284 dietary and medication intake (see **Supplementary Data 1** for this questionnaire).

#### 285 DNA Extraction

DNA was extracted from stool and saliva samples within two weeks of their arrival at the lab. Saliva
extractions were performed using the Isohelix GeneFix Saliva-Prep DNA Kit and stool extractions
using the QIAamp PowerFecal Pro DNA Kit (Qiagen, 51804). DNA quality was assessed using a
Nanodrop One spectrophotometer.

#### 290 SNP Genotyping

291 Salivary DNA samples were genotyped on the Illumina OmniExpress chip at Edinburgh Genomics, 292 according to manufacturer's instructions. Genomic ancestry analysis was performed using principal 293 component analysis (PCA) from this SNP genotype data. Case and HC genotypes were merged with Irish and British ancestry controls from the Irish DNA Atlas<sup>53</sup> (n=193), Irish Trinity Student<sup>54</sup> (n=2,228), 294 and People of the British Isles<sup>55</sup> (n=2,039) using PLINK v1.9<sup>56,57</sup>. We filtered for samples and variants 295 296 with a missingness <5%, and variants with a minor allele frequency <1% and a p-value signifying deviation from Hardy-Weinburg Equilibrium <1e<sup>-9</sup>. We performed PCA on a set of SNPs independent 297 in terms of linkage disequilibrium, using the PLINK --indep-pairwise command with a window of 298 299 1000, step size of 50 and linkage filtering threshold of 0.2. In the case of HC, we performed HLA 300 imputation from these SNP genotypes using SNP2HLA<sup>58</sup>

#### 301 MB Sequencing

302 Gut microbiome DNA samples were shipped to SeqBiome Ltd, Fermoy, County Cork, Ireland. Library 303 construction and shotgun sequencing of autoimmune cases and controls were carried out at 304 SeqBiome Ltd using Nextera library preparation<sup>59</sup> and Illumina NovaSeq sequencing (2 × 150 bp per 305 sample, Illumina, Hayward, California, USA).

Gut microbiome sequence data was then processed initially with *FastQC*<sup>60</sup>, where data quality was visually inspected. All samples were of generally good quality with minimal quality drop off at the end of sequences. *Trimmomatic*<sup>61</sup> was used for trimming and quality filtering using the following parameters: SLIDINGWINDOW:5:22, MINLENGTH:75. The data was then passed to *Kneaddata*, a pipeline incorporating *Trimmomatic*, *Bowtie* 2<sup>62</sup>, and other elements designed for contaminant removal. Taxonomic assignment was then performed using *Kraken2* using a confidence of 0.1 and the

Kraken263,64 GTDB bacterial database65. Kraken2 is a taxonomic classification system using exact k-312 mer matches to achieve high accuracy and fast classification speeds, using a customised version of 313 314 the GTDB database, the results of which were analysed using the R based phyloseq package<sup>66</sup>. GTDB 315 is a database which clusters available genomes based on Average Nucleotide Identity (ANI), and 316 assigns taxonomy based on the National Center for Biotechnology Information (NCBI) classifications. 317 If a sequence does not meet clustering requirements (95% ANI), but does not have a unique 318 taxonomic classification, a suffix will be added to indicate this (e.g., Escherichia coli A). This allows for 319 the most accurate taxonomic classifications, even in the case of organisms which have yet to be 320 formally identified.

Pathway and gene family assignment was then performed using *humann3*<sup>36</sup>. The standard Uniref90
 annotation of gene families were collapsed into Kyoto Encyclopedia of Gene and Genomes (KEGG)<sup>35</sup>

323 orthology annotation and further collapsed into KEGG module and then pathway annotation.

#### 324 Comparative Analysis

We used the phyloseq package<sup>66</sup> in R<sup>67</sup> v4.1.3 for comparative alpha diversity, beta diversity and taxonomic analysis, using the package *ALDEx2*<sup>37</sup>, to determine if any species were differentially abundant (at group level) based on a Kruskal-Wallis test, using 512 Monte-Carlo instances drawn from the Dirichlet distribution. P-values were initially corrected for Benjamini-Hochberg multiple testing, and all were > 0.05. We therefore focussed discussion on the species with P-values significant prior to multiple testing correction (< 0.05 prior to correction).

To account for the compositional structure of the Next Generation Sequencing (NGS) generated data and to avoid the likelihood of generating spurious correlations, we first imputed the zeros in the abundance matrices using the count zero multiplicative replacement method (cmultRepl, method II=II"CZM") implemented in the *Compositions* package and applied a centred log-ratio transformation (CLR) using the *codaSeq.clr* function in the *CoDaSeq* package.

Linear discriminant analysis (LDA) effect size estimation was carried out using the *run\_lefse()* function *microbiomeMarker* package in Bioconductor on the species abundance matrix, selecting CPM normalisation method, 100 bootstrap replicates, a Kruskal-Wallis and Wilcoxon p-value cutoff of 0.05 and LDA effect size cutoff of 2. To test HLA-DRB1\*07:01 divergence from Hardy-Weinberg-Equilibrium (HWE) expectations we utilised the R package HardyWeinberg and the function HWExact() to calculate an exact test for the HWE. To test correlations between HLA dosage and F/B ratio we used the R function cortest().

Alpha and Beta diversity analysis was carried out using the *R* packages *vegan* and *phyloseq* and statistical comparison was tested using Kruskal-Wallis tests. Principle Coordinate Analysis (PCA) was carried out using the *PCA* function in *R* using Aitchison distance matrix (CLR + Euclidean distances). To test the significance of groupings in PCA space, Permutational Multivariate Analysis of Variance (PERMANOVA) test was then performed using 999 permutations with significance cut-off value of 0.05. Dispersion homogeneity was tested using the *betadisper* function from *vegan*.

#### 349 Functional Comparison

KEGG pathways and modules were assessed for differential abundance using *Aldex2* based on a Kruskal-Wallis test using 512 Monte-Carlo instances drawn from the Dirichlet distribution. P-values were initially corrected for multiple testing, and all were > 0.05. We therefore focussed discussion on the pathways and modules with P-values significant prior to multiple testing correction (< 0.05 prior to correction). KEGG pathways and KEGG modules were analysed by computing PCAs using Aitchison distances. To test the significance of groupings, PERMANOVA tests were performed on these

distances, using 999 permutations, with a p-value cut-off of 0.05. Dispersion homogeneity was tested
 using the *betadisper* function from *vegan*.

358 To assess the presence of potential bacterial homologs of the human LGI1 protein, a blastp search of

359 the LGI1 protein was run using a database of 64,695 bacterial genomes acquired from the RefSeq

360 database from which proteomes were generated using *Prokka*<sup>68</sup>. Potential homologs were then

361 filtered from these results using cutoffs of >40% identity, >10% coverage and an e-value <1e-10.

362 These potential homologs were then mapped back to the metagenomic data using *blastx* with

363 cutoffs of >80% identity, >80% coverage and an e-value of <1e-6.

# 364 Acknowledgements

We would like to thank all the participants of this study, without whom the work could not have been completed. We would like to thank the help of Bullers and Mrs Rachel Feeney from the OCMS for their help with kit assembly and sample extractions.

## 368 Open access

For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript (AAM) version arising from this submission.

# 371 Funding

372 This work was funded by a grant from the Medical Research Charities Group, the Health Research 373 Board, Ireland, and Epilepsy Ireland (grant code: MRCG-2018-005), and Science Foundation Ireland 374 (SFI) under Grant Number 16/RC/3948 and co-funded under the European Regional Development 375 Fund and by FutureNeuro industry partners. A senior clinical fellowship (to SFI) from the Medical 376 Research Council [MR/V007173/1], Wellcome Trust Fellowship [104079/Z/14/Z], the National 377 Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) (The views expressed 378 are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of 379 Health)

# 380 Competing Interests

SRI has received honoraria/research support from UCB, Immunovant, MedImmun, Roche, Janssen,
Cerebral therapeutics, ADC therapeutics, Brain, CSL Behring, and ONO Pharma, and receives licensed
royalties on patent application WO/2010/046716 entitled 'Neurological Autoimmune Disorders'. And
has filed two other patents entitled "Diagnostic method and therapy" (WO2019211633 and US2021-0071249-A1; PCT application WO202189788A1) and "Biomarkers" (PCT/GB2022/050614 and
WO202189788A1).

# 387 Data Availability

The raw metagenomic sequence data will be made accessible on the European Genome-Phenome
 Archive (EGA) upon publication and will be referred to here.

# 391 References

- 392 1. Scheffer, I.E. et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission 393 for Classification and Terminology. Epilepsia 58, 512-521 (2017). 394 2. Graus, F. et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 395 **15**, 391-404 (2016). 396 3. Steriade, C. et al. Acute symptomatic seizures secondary to autoimmune encephalitis and 397 autoimmune-associated epilepsy: Conceptual definitions. Epilepsia 61, 1341-1351 (2020). 398 4. Brenner, T. et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and 399 established epilepsy. Epilepsia 54, 1028-35 (2013). 400 5. Thompson, J. et al. The importance of early immunotherapy in patients with faciobrachial 401 dystonic seizures. Brain (2017). 402 6. Irani, S.R. et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann 403 Neurol 69, 892-900 (2011). 404 7. Irani, S.R. et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure 405 control and prevention of cognitive impairment in a broadening phenotype. Brain 136, 3151-406 62 (2013). Aurangzeb, S. et al. LGI1-antibody encephalitis is characterised by frequent, multifocal 407 8. 408 clinical and subclinical seizures. Seizure 50, 14-17 (2017). 409 9. Finke, C. et al. Evaluation of Cognitive Deficits and Structural Hippocampal Damage in 410 Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies. JAMA Neurol 74, 50-59 411 (2017).412 10. Gadoth, A. et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive 413 patients. Ann Neurol 82, 79-92 (2017). 414 11. Bien, C.G. et al. Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcome. Eur J Neurol 24, 175-186 (2017). 415 416 12. Irani, S.R. et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma 417 inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's 418 syndrome and acquired neuromyotonia. Brain 133, 2734-48 (2010). 419 13. Shin, Y.W. et al. VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and 420 response to immunotherapy. J Neuroimmunol 265, 75-81 (2013). 421 14. Flanagan, E.P. et al. Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial 422 dystonic seizures. Neurol Neuroimmunol Neuroinflamm 2, e161 (2015). 423 15. Binks, S.N.M., Klein, C.J., Waters, P., Pittock, S.J. & Irani, S.R. LGI1, CASPR2 and related 424 antibodies: a molecular evolution of the phenotypes. J Neurol Neurosurg Psychiatry (2017). 425 16. Binks, S.N.M. et al. Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-426 antibody encephalitis. Ann Clin Transl Neurol (2024). 427 17. Smith, K.M., Dubey, D., Liebo, G.B., Flanagan, E.P. & Britton, J.W. Clinical Course and Features 428 of Seizures Associated With LGI1-Antibody Encephalitis. *Neurology* 97, e1141-e1149 (2021). 429 18. van Sonderen, A. et al. Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-430 DRB4. Ann Neurol 81, 193-198 (2017). 431 19. Kim, T.J. et al. Anti-LGI1 encephalitis is associated with unique HLA subtypes. Ann Neurol 81, 432 183-192 (2017). 433 20. Muniz-Castrillo, S. et al. Anti-CASPR2 clinical phenotypes correlate with HLA and 434 immunological features. J Neurol Neurosurg Psychiatry 91, 1076-1084 (2020). 435 21. Binks, S. et al. Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain 141, 436 2263-2271 (2018). 437 22. Creary, L.E. et al. High-resolution HLA allele and haplotype frequencies in several unrelated 438 populations determined by next generation sequencing: 17th International HLA and 439 Immunogenetics Workshop joint report. Hum Immunol 82, 505-522 (2021). 440 23. Tremlett, H., Bauer, K.C., Appel-Cresswell, S., Finlay, B.B. & Waubant, E. The gut microbiome
- 441 in human neurological disease: A review. Ann Neurol **81**, 369-382 (2017).

442 443	24.	Sharon, G., Sampson, T.R., Geschwind, D.H. & Mazmanian, S.K. The Central Nervous System and the Gut Microbiome. <i>Cell</i> <b>167</b> , 915-932 (2016).
444	25	McKay K A <i>et al.</i> From bugs to brains: The microbiome in neurological health <i>Mult Scler</i>
445	23.	Relat Disord <b>12</b> , 1-3 (2017).
446	26.	van der Vossen, E.W.J., de Goffau, M.C., Levin, E. & Nieuwdorp, M. Recent insights into the
447		role of microbiome in the pathogenesis of obesity. Therap Adv Gastroenterol 15,
448		17562848221115320 (2022).
449	27.	Yao, S., Zhao, Z., Wang, W. & Liu, X. Bifidobacterium Longum: Protection against
450		Inflammatory Bowel Disease. <i>J Immunol Res</i> <b>2021</b> , 8030297 (2021).
451	28.	Silva, Y.P., Bernardi, A. & Frozza, R.L. The Role of Short-Chain Fatty Acids From Gut Microbiota
452		in Gut-Brain Communication. Front Endocrinol (Lausanne) 11, 25 (2020).
453	29.	Piquer-Esteban, S., Ruiz-Ruiz, S., Arnau, V., Diaz, W. & Moya, A. Exploring the universal
454		healthy human gut microbiota around the World. Comput Struct Biotechnol J 20, 421-433
455		(2022).
456	30.	Oren, A., Arahal, D.R., Rossello-Mora, R., Sutcliffe, I.C. & Moore, E.R.B. Emendation of Rules
457		5b, 8, 15 and 22 of the International Code of Nomenclature of Prokaryotes to include the
458		rank of phylum. Int J Syst Evol Microbiol <b>71</b> (2021).
459	31.	Oren, A. & Garrity, G.M. Valid publication of the names of forty-two phyla of prokaryotes. Int
460		J Syst Evol Microbiol <b>71</b> (2021).
461	32.	Magne, F. <i>et al.</i> The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in
462		Obese Patients? Nutrients 12(2020).
463	33.	Sorboni, S.G., Moghaddam, H.S., Jafarzadeh-Esfehani, R. & Soleimanpour, S. A
464		Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders.
465		Clin Microbiol Rev <b>35</b> . e0033820 (2022).
466	34.	Stojanov, S., Berlec, A. & Strukeli, B. The Influence of Probiotics on the
467		Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease.
468		Microorganisms 8(2020).
469	35.	Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG; new perspectives on
470		genomes, pathways, diseases and drugs, <i>Nucleic Acids Res</i> 45, D353-D361 (2017).
471	36.	Beghini, E. et al. Integrating taxonomic, functional, and strain-level profiling of diverse
472		microbial communities with bioBakery 3. <i>Elife</i> <b>10</b> (2021).
473	37.	Fernandes, A.D., Macklaim, J.M., Linn, T.G., Reid, G. & Gloor, G.B. ANOVA-like differential
474		expression (ALDEx) analysis for mixed population RNA-Seq. <i>PLoS One</i> 8, e67019 (2013).
475	38.	Ding, M., Lang, Y., Shu, H., Shao, J. & Cui, L. Microbiota-Gut-Brain Axis and Epilepsy: A Review
476		on Mechanisms and Potential Therapeutics. Front Immunol <b>12</b> , 742449 (2021).
477	39.	Kim. S., Park. S., Choi, T.G. & Kim. S.S. Role of Short Chain Fatty Acids in Epilepsy and
478		Potential Benefits of Probiotics and Prebiotics: Targeting "Health" of Epileptic Patients.
479		Nutrients <b>14</b> (2022).
480	40	Neis EP Deiong CH & Rensen SS The role of microbial amino acid metabolism in host
481		metabolism. Nutrients 7, 2930-46 (2015).
482	41	Peterson CT <i>et al.</i> Short-Chain Fatty Acids Modulate Healthy Gut Microbiota Composition
483		and Functional Potential Curr Microbiol <b>79</b> , 128 (2022)
484	42	Mills S Yang B Smith G I Stanton C & Ross R P Efficacy of Bifidobacterium longum
485		alone or in multi-strain probiotic formulations during early life and beyond <i>Gut Microbes</i> 15
486		2186098 (2023).
487	43.	Ilhan, Z.E., Brochard, V., Lapaque, N., Auvin, S. & Lenage, P. Exposure to anti-seizure
488		medications impact growth of gut bacterial species and subsequent host response. Neurophol
489		Dis 167. 105664 (2022).
490	44.	Zhou, C. <i>et al.</i> Changes and significance of gut microbiota in children with focal epilepsy
491		before and after treatment. Front Cell Infect Microbiol <b>12</b> , 965471 (2022).

492	45.	De Caro, C. et al. Intestinal inflammation increases convulsant activity and reduces
493		antiepileptic drug efficacy in a mouse model of epilepsy. <i>Sci Rep</i> <b>9</b> , 13983 (2019).
494	46.	Lee, K., Kim, N., Shim, J.O. & Kim, G.H. Gut Bacterial Dysbiosis in Children with Intractable
495		Epilepsy. J Clin Med 10(2020).
496	47.	Chatzikonstantinou, S. <i>et al.</i> The gut microbiome in drug-resistant epilepsy. <i>Epilepsia Open</i> 6,
497		28-37 (2021).
498	48.	Ma, X. et al. Clinical Features and Gut Microbial Alterations in Anti-leucine-rich Glioma-
499		Inactivated 1 Encephalitis-A Pilot Study. <i>Front Neurol</i> <b>11</b> , 585977 (2020).
500	49.	Mohiti A, A.M., Amooei M,. The Effect of Systemic Corticosteroid Use on the pH and Viscosity
501		of Saliva. <i>Shiraz E-Medical Journal</i> <b>22</b> , e101710 (2020).
502	50.	Lindefeldt, M. et al. The ketogenic diet influences taxonomic and functional composition of
503		the gut microbiota in children with severe epilepsy. NPJ Biofilms Microbiomes <b>5</b> , 5 (2019).
504	51.	Attaye, I., van Oppenraaij, S., Warmbrunn, M.V. & Nieuwdorp, M. The Role of the Gut
505		Microbiota on the Beneficial Effects of Ketogenic Diets. <i>Nutrients</i> <b>14</b> (2021).
506	52.	Ghosh, T.S., Shanahan, F. & O'Toole, P.W. The gut microbiome as a modulator of healthy
507		ageing. Nat Rev Gastroenterol Hepatol 19, 565-584 (2022).
508	53.	Gilbert, E. <i>et al.</i> The Irish DNA Atlas: Revealing Fine-Scale Population Structure and History
509		within Ireland. <i>Sci Rep</i> <b>7</b> , 17199 (2017).
510	54.	Desch, K.C. <i>et al.</i> Linkage analysis identifies a locus for plasma von Willebrand factor
511		undetected by genome-wide association. Proc Natl Acad Sci U S A <b>110</b> , 588-93 (2013).
512	55.	Winney, B. <i>et al.</i> People of the British Isles: preliminary analysis of genotypes and surnames
513		in a UK-control population. <i>Eur J Hum Genet</i> <b>20</b> , 203-10 (2012).
514	56.	Chang, C.C. <i>et al.</i> Second-generation PLINK: rising to the challenge of larger and richer
515		datasets. Gigascience 4, 7 (2015).
516	57.	Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage
517		analyses. Am J Hum Genet <b>81</b> , 559-75 (2007).
518	58.	Jia, X. et al. Imputing Amino Acid Polymorphisms in Human Leukocyte Antigens. PLOS ONE 8,
519		e64683 (2013).
520	59.	Christie, W., Yadin, R., Ip, K. & George, K.W. Highly Multiplexed, Semiautomated Nextera
521		Next-Generation Sequencing (NGS) Library Preparation. Methods Mol Biol 2205, 91-104
522		(2020).
523	60.	Andrews, S. FastQC: A Quality Control Tool for High Throughput Sequence Data. (2010).
524	61.	Bolger, A.M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence
525		data. <i>Bioinformatics</i> <b>30</b> , 2114-20 (2014).
526	62.	Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat Methods <b>9</b> ,
527		357-9 (2012).
528	63.	Wood, D.E. & Salzberg, S.L. Kraken: ultrafast metagenomic sequence classification using
529		exact alignments. <i>Genome Biol</i> <b>15</b> , R46 (2014).
530	64.	Wood, D.E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2. Genome
531		Biol <b>20</b> , 257 (2019).
532	65.	Parks, D.H. <i>et al.</i> GTDB: an ongoing census of bacterial and archaeal diversity through a
533		phylogenetically consistent, rank normalized and complete genome-based taxonomy. Nucleic
534		Acids Res <b>50</b> , D785-D794 (2022).
535	66.	McMurdie, P.J. & Holmes, S. phyloseq: an R package for reproducible interactive analysis and
536		graphics of microbiome census data. <i>PLoS One</i> <b>8</b> , e61217 (2013).
537	67.	Team., R.C. R: A language and environment for statistical computing. <i>R Foundation for</i>
538		Statistical Computing. (2017).
539	68.	Seemann, T. Prokka: rapid prokaryotic genome annotation. <i>Bioinformatics</i> <b>30</b> , 2068-9 (2014).

# 541 Figures and Tables

# 542 Table 1

	Cases				
	LG 1	CASPR2	LGI1/CASPR2	Healthy controls	
No. of patients*	43	3	1	27	
Control type:	NA	NA	NA		
Spouse/partner				15/27 (56%)	
Sibling				1/27 (4%)	
Child				1/27 (4%)	
Other				3/27 (11%)	
Unknown				6/27 (22%)	
Mean (median) age at sampling**	66 (66)	69 (69)	60 (NA)	ΝΔ	
Sev female %*	8/13 (19%)	3 (100%)	1 (100%)	NA	
Sex, Terriale, 70	8/43 (19%)	5 (100%)	1 (100%)		
Clinical syndrome, %:				NA	
Fnilensy	2/43	0	0		
Limbic encentralitis	2,43	3 (100%)	0		
Moryan's syndrome	0/43	0	1 (100%)		
Neuromyotonia/nain	0/43 //13	1 (33%)	1 (100%)		
NA	2/42	1(35%)	0		
	2743	0	0		
Medications at time of sampling, %:				NA	
Anti-seizure:					
Carbamazepine	1/43 (2%)	1 (33%)	0		
Clobazam/Clonazepam/Lorazepam	2/43 (5%)	ò	0		
Gabapentin/Pregabalin	3/43 (7%)	2/3 (66%)	1 (100%)		
Lacosamide	1/43 (2%)	0	, o ,		
Lamotrigine	5/43 (12%)	0	0		
Levetiracetam	15/43 (35%)	2/3 (66%)	0		
Phenvtoin	1/43 (2%)	0	1 (100%)		
Valproate	6/43 (14%)	0	`о́		
None	10/43 (23%)	0	0		
NA	3/43 (7%)	0	0		
Immunotherapy:		_	_		
Azathioprine	1/43 (2%)	0	0		
Corticosteroids	23/43 (53%)	3/3 (100%)	1 (100%)		
Mycophenolate Mofetil	2/43 (5%)	0	0		
None	15/43 (35%)	0	0		
NA	3/43 (7%)	0	0		
HLA status, %:					
DRB1*07:01 carrier	39/43 (91%)	1/3 (33%)	0	11/27 (41%)	
DRB1*07:01 homozvgote	4/43 (10%)	0	0	1/27 (4%)	
DRB1*07:01 negative	3/43 (7%)	2/3 (66%)	1 (100%)	4/27 (15%)	
Unknown	0	0	0	11/27 (41%)***	
*No antibody status or sex for one patient **No age at sampling for three patients *** HLA imputation was					
used for HC and some imputed HLA genotypes did not pass quality control for sufficient carrier status to be					

called.

544

545 Study Cohort Characteristics - Shown are the cohort descriptors for 47 LGI1-CASPR2-Ab-E cases and 546 27 matched health controls. Cohort is characterised by; genetic sex (Sex), auto-antibody status if a 547 case (Case Type), whether an individual is inferred to be a HLA DRB\*07:01 carrier through imputation 548 (HLA DRB Status), and what relationship the health control has with matched case (HC Type).





<sup>551</sup> 552

553 Comparison of the gut microbiome in LGI1-CASPR2-Ab-E cases and healthy controls – (A) Bar chart 554 of the 20 most abundant Genera, grouped by Phylum and separating cases (left) and healthy control 555 (HC) samples (right) in separate panels. Each vertical bar represents the compositional microbiome 556 profile of an individual. Note: Firmicutes A and similar names are placeholder taxa which have been 557 classified as such in the NCBI database but does not meet the clustering requirements for GTDB. 558 Unused space represents other species not in the top 20 most abundant. (B) The distribution of 559 alpha diversity values between cases (orange) and HC (green) using two measures, the Inverse 560 Simpson and Shannon to retain comparative direction of effect between the two. Pairwise p-values 561 shown are Wilcoxon test p-values significant after Holm correction for multiple testing (Shannon not 562 significant). (C) Principal Component Analysis of beta-diversity estimates between cases and HC. 563 Ellipses shown are 80% confidence intervals assuming a multivariate t-distribution.

#### 565 Table 2

GTDB Species	NCBI Species	Effect	Uncorrected P-value
Streptococcus parasanguinis_B	Streptococcus parasanguinis	-0.347	0.007
Streptococcus salivarius	Streptococcus salivarius	-0.302	0.013
Vei <b>l</b> lone <b>ll</b> a atypica	Vei <b>ll</b> one <b>ll</b> a atypica	-0.43	0.015
NK3B98 sp900545815	uncultured Eubacteriales bacterium	0.307	0.015
Haemophilus_D parainfluenzae	Haemophilus parainfluenzae	-0.302	0.017
GCA-900066995 sp900291955	Pseudoruminococcus massiliensis	0.29	0.019
Haemophilus_D parainfluenzae_K	Haemophilus parainfluenzae	-0.403	0.021
UMGS1071 sp900542375	uncultured Oscillospiraceae bacterium	0.354	0.024
Faecalibacterium prausnitzii_A	Faecalibacterium prausnitzii	-0.234	0.025
Streptococcus sp001556435	Streptococcus salivarius	<b>-</b> 0.334	0.027
Veillonella dispar_A	Veillone <b>ll</b> a dispar	-0.392	0.028
Alistipes_A sp900240235	uncultured Alistipes sp.	0.397	0.032
Coprococcus sp900066115	Coprococcus sp.	0.281	0.041
COE1 sp001916965	Roseburia sp.	-0.28	0.042
Streptococcus vestibularis	Streptococcus vestibularis	-0.358	0.048
Bifidobacterium dentium	Bifidobacterium dentium	-0.366	0.048

566

567

568 **Differential gut microbiome species between** *LGI1-CASPR2-Ab-E* cases and healthy controls – 569 Shown are the 16 differentiated species which have significant, uncorrected for multiple testing, p-570 values using the Kruskal-Wallis test using 512 Monte-Carlo instances drawn from the Dirichlet 571 distribution. A positive value indicating an enrichment in HC samples.

#### 574 Figure 2



575

576 **Differential enrichment of microbiome taxa in** *LG11-CASPR2***-Ab-E cases and healthy controls** - Taxa 577 significantly (adjusted p-value < 0.05) enriched in either healthy controls (HC) or cases. Points are 578 colour coded according to the sample type the taxon is enriched in, and the log<sub>10</sub>(LDA) score (effect 579 size) is shown along the x-axis. Labels along the y-axis are in the format of "p:" to indicate phylum, 580 "g:" to indicate genus, and "s:" to indicate species with "->" joining parent and child taxa. 581

#### 582 Table 3

	Table 3           Differential KEGG Components		
	Name	Effect	Uncorrected P-value
KEGG Module	Coenzyme A biosynthesis, pantothenate => CoA	0.468	0.0033
	Ornithine biosynthesis, glutamate => ornithine	0.369	0.023
	Histidine biosynthesis, PRPP => histidine	0.314	0.037
KEGG Pathway	Pentose and glucuronate interconversions	-0.472	0.0031
	Ribosome biogenesis in eukaryotes	0.358	0.0082
	Parkinson disease	0.369	0.021
	NOD-like receptor signaling pathway	0.346	0.022
	Necroptosis	0.325	0.039

583 584

Differential KEGG modules between LGI1-CASPR2-Ab-E cases and healthy controls - Shown are the
 three differentiated KEGG Modules, and the five KEGG Pathways which have significant, uncorrected
 for multiple testing, p-values using the Kruskal-Wallis test using 512 Monte-Carlo instances drawn
 from the Dirichlet distribution. A positive value indicating an enrichment in healthy control samples.





**Supplementary Figure 1 – Ancestry PCA of** *LGI1-CASPR2-Ab-E* **Cases and Controls**. The principal component decomposition of a genetic relationship matrix of 4,460 Irish and British ancestry controls and 47 cases and 27 health controls (HC). Points are colour and shape coded according to genetic ancestry group. Filled circles with red indicate the genetic position of a case and filled circles

- 598 with white indicate the genetic position of a HC.
- 599



600

501 Supplemental Figure 2 -Filtering quality of LG11-CASPR2-Ab-E case and healthy control gut 502 microbiome samples. Boxplot representation of percentage of reads which pass the quality filtering 503 step, coloured by sample type. Boxplots show the median value, with lower and upper hinges 504 showing the 1st and 3rd quartiles. Whiskers show the largest value no further than 1.5 x the 505 Interquartile Range (IQR) from that range. Data points beyond these whiskeys are plotted separately 506 as black points.

607



609

610 Supplemental Figure 3: Kraken2 percent classification of *LG11-CASPR2*-Ab-E case and healthy 611 control reads. Boxplots show the median value, with lower and upper hinges showing the 1st and 612 3rd quartiles. Whiskers show the largest value no further than 1.5 x the Interquartile Range (IQR)



616 **Supplemental Figure 4:** *Firmicutes/Bacteroides* ratio in *LGI1-CASPR2*-Ab-E cases and healthy 617 **controls.** (A) The proportion of the two phyla *Firmicutes* and *Bacteroides* in cases and healthy 618 controls (HC). Comparison bars shown are the p value from Wilcox Signed Rank test. (B) The 619 *Firmicutes/Bacteroides* ratio between cases and HC. Individual data points are shown on top of 620 boxplots. Boxplots show the median value, with lower and upper hinges showing the 1st and 3rd 621 quartiles. Whiskers show the largest value no further than 1.5 x the Interquartile Range (IQR) from 622 that range.



624

Carrier Status of HLA-DBR\*0701

Supplemental Figure 5: Firmicutes/Bacteroides ratio as a function of HLA-DBR\*0701 dosage. The ratio of the two phyla Firmicutes and Bacteroides in LGI1- Ab-E cases and healthy controls (HC) grouped by HLA-DBR\*0701 dosage. As HC HLA-DRB1\*0701 dosage was imputed from SNP genotypes there is a proportion of missing data. Individual data points are shown on top of boxplots. Boxplots show the median value, with lower and upper hinges showing the 1st and 3rd quartiles. Whiskers

630 show the largest value no further than 1.5 x the Interquartile Range (IQR) from that range.



631 632

633 **Supplemental Figure 6 - Measure of Alpha diversity stratified by case type.** Shown are the Inverse 634 Simpson and Shannon alpha diversity measurements. Distributions of alpha diversity values are 635 shown in boxplots. Boxplots show the median value, with lower and upper hinges showing the 1<sup>st</sup> 636 and 3<sup>rd</sup> quartiles. Whiskers show the largest value no further than 1.5 x the Interquartile Range (IQR) 637 from that range. Data points beyond these whiskeys are plotted separately as black points. 638



540 Supplemental Figure 7 – Distribution of LGI1-CASPR2-Ab-E cases and controls over beta-diversity 541 principal components. Shown are the sample distributions across the first three Aitchison principal 542 components of beta diversity, with violin plots showing overall distribution. Pairwise comparison 543 values are significant p-values from Wilcox tests of significant differences. All comparison pairs were 544 tested, and p-values adjusted with the Holm method.



Supplemental Figure 8 – Aitchison PCA of KEGG Pathway abundance. Sample case and control type
 are shown by colour and shape. Ellipses shown are 80% confidence intervals assuming a multivariate
 t-distribution.

651

KEGG Module PCA





Supplemental Figure 9 – Aitchison PCA of KEGG Module abundance. Sample case and control type
 are shown by colour and shape. Ellipses shown are 80% confidence intervals assuming a multivariate
 t-distribution.



**Supplemental Figure 10 – Differential enrichment of microbiome taxa in** *LGI1-CASPR2***-Ab-E cases stratified by steroid use history and healthy controls** - Taxa significantly (adjusted p-value < 0.05) enriched in either healthy controls (HC) or cases. Points are colour coded according to the sample type the taxon is enriched in, and the log<sub>10</sub>(LDA) score (effect size) is shown along the x-axis. Labels along the y-axis are in the format of "p:" to indicate phylum, "g:" to indicate genus, and "s:" to indicate species with "->" joining parent and child taxa.

- 664
- 665 Supplemental Data 1 Dietary and supplement questionnaire
- 666 Supplemental Data 2 Species
- 667 Supplemental Data 3 LDA Taxa results
- 668 Supplemental Data 4 Dietary associations with beta-PCs
- 669 Supplemental Data 5 All KEGG Module results
- 670 Supplemental Data 6 All KEGG Pathway results
- 671 Supplemental Data 7 Organism orthologues